GLP-1 Medications: A Clinical Guide for UAE Patients

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) have generated extraordinary clinical results in obesity medicine — with trial data showing 15–22% body weight reduction, improvements in cardiovascular outcomes, liver disease, sleep apnoea, and metabolic markers across the board.

This guide explains the science, the protocols, and what you need to know as a patient.

How GLP-1 Medications Work

GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally released from the gut after eating. GLP-1 receptor agonists mimic this hormone at supraphysiological levels, producing several simultaneous effects:

1. Appetite Suppression (Central)

GLP-1 receptors in the hypothalamus and brainstem reduce hunger signals — particularly cravings for high-calorie foods. Patients consistently report the "food noise" (intrusive thoughts about food) disappearing entirely within weeks.

2. Gastric Emptying Delay

Food moves more slowly from the stomach to the small intestine, extending the feeling of fullness after meals and reducing total caloric intake naturally.

3. Insulin Secretion (Glucose-Dependent)

GLP-1 agonists stimulate insulin release only when blood sugar is elevated — meaning they cannot cause hypoglycemia (low blood sugar) in non-diabetic patients.

4. Glucagon Suppression

By reducing glucagon (the hormone that raises blood sugar), these medications improve postprandial glucose control and reduce hepatic glucose output.

Semaglutide vs Tirzepatide: Key Differences

| | Semaglutide | Tirzepatide | |--|--|--| | Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist | | Average weight loss | 15–17% | 19–22% | | Dosing | Weekly injection | Weekly injection | | CV outcome data | Proven (SUSTAIN, SELECT) | Emerging (SURMOUNT) | | Available in UAE | Yes | Yes |

Tirzepatide's additional GIP (Glucose-dependent Insulinotropic Polypeptide) agonism appears to produce superior metabolic effects — particularly on body composition (more fat loss, better preservation of lean mass).

Who Qualifies for GLP-1 Therapy?

Clinical eligibility criteria used in our protocols:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, NAFLD)

Contraindications include:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia type 2 (MEN2)
• Severe gastroparesis
• Pancreatitis (active or history)
• Pregnancy or breastfeeding

Required Blood Work Before Starting

Our protocol requires the following baseline panel before initiating treatment:

• HbA1c and fasting glucose
• Full lipid panel
• Liver function tests (ALT, AST, GGT)
• Kidney function (creatinine, eGFR)
• Thyroid panel (TSH, Free T3, Free T4)
• Amylase and lipase (pancreatic enzymes)
• Full blood count
• Comprehensive metabolic markers

This is not optional — it protects you and allows us to monitor your response safely.

Dosing Protocol

Semaglutide Titration:

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Week 13+: 1.7 mg or 2.4 mg (maintenance, weight management dose)

Tirzepatide Titration:

• Weeks 1–4: 2.5 mg weekly
• Weeks 5–8: 5.0 mg weekly
• Weeks 9–12: 7.5 mg weekly
• Week 13–20: 10–15 mg weekly (maximum dose)

Slow titration dramatically reduces GI side effects (nausea, vomiting) that often cause early discontinuation.

What to Expect: A Timeline

Weeks 1–4: Reduced appetite noticeable. Some nausea, especially after eating — manageable with slow eating and small portions.

Months 2–3: Significant reduction in cravings. Early weight loss of 2–5 kg typical.

Months 3–6: Peak appetite suppression. Weight loss accelerates. Most patients report effortless caloric reduction.

Months 6–12: Continued steady loss. Average patients on full-dose semaglutide lose 12–17% of starting body weight.

Side Effects and Management

Common (usually temporary):

• Nausea (most common, improves with titration)
• Constipation
• Fatigue during dose increases
• Reduced appetite (intended effect)

Less common:

• Vomiting (mitigated by eating slowly, small meals)
• Mild hair thinning (nutritional — ensure adequate protein intake)

Rare but serious:

• Pancreatitis (stop medication, seek emergency care if severe abdominal pain)
• Gallbladder disease (rapid weight loss increases risk — monitor with ultrasound if symptomatic)

Monitoring During Treatment

Our protocol includes:

• Blood work at 3 and 6 months (HbA1c, lipids, liver enzymes, kidney function)
• Body composition measurement (not just weight — muscle mass preservation is critical)
• Monthly clinical reviews

The Importance of Lifestyle Integration

GLP-1 medications are powerful tools — not standalone solutions. Patients who combine medication with:

• Adequate protein intake (1.6–2.2 g/kg bodyweight) to preserve muscle mass
• Resistance training to prevent sarcopenia
• Nutritional coaching to optimize food choices within reduced appetite

...achieve far superior long-term outcomes compared to medication alone.

---

This article is for educational and informational purposes only. GLP-1 medications must be prescribed and monitored by a qualified physician. Always consult your doctor before starting any treatment.